Serum protein binding of tolbutamide in patients treated with antiepileptic drugs.
The possible development of a displacement interaction involving tolbutamide, in epileptic patients, has been explored by studying the serum protein binding of this drug in vitro in 199 samples of sera from patients treated with antiepileptic agents included in a programme of therapeutic drug monitoring. 82 of the samples were from patients receiving a single drug, 86 from patients treated with 2 drugs, and 31 from patients treated with 3 drugs. The free fraction of tolbutamide was higher in serum from patients treated with antiepileptic drugs than in serum from untreated 'normal' volunteers. The increase was more marked the greater the number of antiepileptic drugs administered. Valproate appeared to be the most powerful displacing agent.
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000097:blood; D001667:Binding, Competitive; D001798:Blood Proteins / Q000378:metabolism*; D002648:Child; D002998:Clonazepam / Q000494:pharmacology; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000494:pharmacology; D010672:Phenytoin / Q000494:pharmacology; D011485:Protein Binding; D014044:Tolbutamide / Q000097:blood*; D014635:Valproic Acid / Q000494:pharmacology
D000927:Anticonvulsants; D001798:Blood Proteins; D002998:Clonazepam; D014635:Valproic Acid; D010672:Phenytoin; D014044:Tolbutamide; D010634:Phenobarbital